BMN-111 is an emergent treatment for achondroplasia. It is now in a Phase III clinical trial and aims to bring a treatment to the condition. In this article you can read more on how it works, its strong suits and drawbacks.

Meclozine (or Meclizine) is an over-the-counter drug for motion sickness that has been shown to be a potential treatment for achondroplasia by Prof. Matsushita. It has already been tested in mice and dogs and is heading for Phase I.

RMB-007 is a potential drug being developed by Ribomic Inc., a Japanese biotech company. It is still in development and is still in pre-clinical studies.

TA-46 is a soluble form of FGFR3. This receptor that exists in chondrocytes is where is the mutation in achondroplasia is located. Phase 1 clinical trials for this molecule will start in early 2018. Learn more about how it works and how far it is in development here.

TransCon CNP is a new molecule for achondroplasia under development by Ascendis Pharma. Its mechanism of action is similar to the one used by Vosoritide, but with a modification in a formulation that makes a big difference. Learn more about it here.